A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Pomalidomide and Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma Previously Treated With One Line Therapy Who Are Lenalidomide Refractory

Name: A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Pomalidomide and Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma Previously Treated With One Line Therapy Who Are Lenalidomide Refractory
Published: 2022
License: Public Domain

Hellenic Society of Hematology · 2022

ClinicalTrials.gov · Datasets · License: Public Domain · 2022

Open Source ↗

monoclonal multiple-myeloma neoplasms

multiple myeloma, multiple myeloma in relapse, neoplasms, gammopathy, monoclonal, paraproteinemias, blood protein disorders, haematologic disease, corneal disease, neoplasms, plasma cell, interventional, phase1, phase2

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Pomalidomide and Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma Previously Treated With One Line Therapy Who Are Lenalidomide Refractory

Related documents